97 related articles for article (PubMed ID: 7516378)
21. Medical management of benign prostatic hyperplasia: a review.
Magoha GA
East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007
[TBL] [Abstract][Full Text] [Related]
22. [The current approach to the management of benign hypertrophy of the prostate].
Abbou CC; Salomon L; Chopin D; Ravery V; Haillot O
Ann Urol (Paris); 1996; 30(6-7):294-301; discussion 302-10. PubMed ID: 9092383
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
24. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
Jolliet P; Bourin M
Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of benign prostatic hypertrophy with gestonorone caproate].
Baranowska B; Kuzaka B
Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):999-1003. PubMed ID: 6209689
[No Abstract] [Full Text] [Related]
27. [Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Van Cangh PJ
Bull Mem Acad R Med Belg; 1992; 147(1-2):125-35; discussion 135-7. PubMed ID: 1384903
[TBL] [Abstract][Full Text] [Related]
28. [Recent progress in the medical treatment of benign prostatic hyperplasia].
Cornu JN; Rouprêt M
Prog Urol; 2007 Sep; 17(5 Suppl 1):1029-32. PubMed ID: 17969785
[TBL] [Abstract][Full Text] [Related]
29. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].
Di Silverio F
Minerva Urol Nefrol; 1986; 38(2):163-71. PubMed ID: 2428120
[No Abstract] [Full Text] [Related]
30. [Androgen deprivation in benign prostatic hypertrophy].
Tenaglia R; Nicolai M; Di Federico G; Iantorno R; Zezza A; Lombardi G
J Urol (Paris); 1993; 99(6):296-8. PubMed ID: 7516371
[TBL] [Abstract][Full Text] [Related]
31. [Cyproterone acetate in benign prostatic hypertrophy].
Cocimano V; Marino G; Surleti D; Brigato R; Griffa D
Minerva Urol Nefrol; 1989; 41(4):275-6. PubMed ID: 2483594
[TBL] [Abstract][Full Text] [Related]
32. Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate.
Orestano F; Altwein JE
Br J Urol; 1976 Dec; 48(6):485-91. PubMed ID: 64267
[TBL] [Abstract][Full Text] [Related]
33. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year.
Romics I; Schmitz H; Frang D
Int Urol Nephrol; 1993; 25(6):565-9. PubMed ID: 7513678
[TBL] [Abstract][Full Text] [Related]
34. [Echotomographic evaluation of the recent endocrine trends in the treatment of so-called prostatic hypertrophy].
Napolitano A; Gargano E; Criniti P; Zezza A; Seccia M; Galfano G
Ann Ital Chir; 1983; 55(2):161-7. PubMed ID: 6197917
[No Abstract] [Full Text] [Related]
35. [Current therapy of benign prostatic hypertrophy].
Rist M
Schweiz Rundsch Med Prax; 1986 Jul; 75(29):875-6. PubMed ID: 2426754
[No Abstract] [Full Text] [Related]
36. Endocrine treatment of benign prostatic hypertrophy: current concepts.
Matzkin H; Braf Z
Urology; 1991 Jan; 37(1):1-16. PubMed ID: 1702565
[TBL] [Abstract][Full Text] [Related]
37. [The conservative treatment of early-stage benign prostatic hypertrophy].
Kumanov Kh; Stoianova V; Lilov A; Kaloianov D
Khirurgiia (Sofiia); 1993; 46(5):5-6. PubMed ID: 7527092
[TBL] [Abstract][Full Text] [Related]
38. [Gestonorone therapy of prostatic adenoma].
Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
[TBL] [Abstract][Full Text] [Related]
39. [Effect of estradiol, diethylstilbestrol, progesterone, and gestonorone capronate (depostat) on the 5 alpha-reductase kinetics in benign prostatic hypertrophy (BPH) (author's transl)].
Altwein JE; Rubin A; Klose K; Knapstein P; Orestano F
Urologe A; 1974 Jan; 13(1):41-6. PubMed ID: 4132876
[No Abstract] [Full Text] [Related]
40. Depostat for benign prostatic hyperplasia?
Drug Ther Bull; 1973 Sep; 11(19):75-6. PubMed ID: 4130364
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
